STAT Plus: Despite investments and advocacy, pharma’s still making its drugs in batches that can take months — rather than continuously. Why?

WASHINGTON — Former FDA Commissioner Scott Gottlieb said so-called continuous manufacturing would prevent drug shortages, lower drug prices, and bring manufacturing back to the United States. Lawmakers have doled out millions to encourage it. There are predictions it could throw gasoline on the quest for flu treatments and now, potentially, coronavirus therapies.

So why aren’t most drug makers fully bought in?

Continue to STAT Plus to read the full story…

Read Original Article: STAT Plus: Despite investments and advocacy, pharma’s still making its drugs in batches that can take months — rather than continuously. Why? »